Special issues related to breast cancer adjuvant therapy in older women

Witherby, Sabrina M.; Muss, Hyman B.

doi:10.1016/j.breast.2005.08.015

Cited by 18 publications

(10 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Over half of all breast cancers occur in older women. 6 There is evidence, though, that older women are less likely to receive therapy than younger women. 7 Anticipated life expectancy, comorbidity and functional status all influence the decision on whether or not to offer adjuvant irradiation.…”

Section: Breast Cancer In Older Patientsmentioning

confidence: 99%

“…Only 9% of the 16,396 patients entered into trials of the US South West Oncology Group between 1993 and 1996 were aged 65 years or older. 6 In clinical practice, the results of trials in younger women have been extrapolated to older women, even in the absence of a solid evidence base in this age group. The Oxford Overview 18 recently demonstrated, however, that the level of 5-year risk of local recurrence falls with age for both irradiated and non-irradiated patients (to 3% with radiotherapy vs 13% without radiotherapy at age ജ70 years), as does the absolute reduction (from 22% at age ജ50 to 11% at age ജ70 years).…”

Section: The Need For Clinical Trials In Older Patientsmentioning

confidence: 99%

“…Methodologies to integrate the prediction of recurrence rates from breast cancer with the competing effects of mortality from other diseases need to be refined to improve clinical decision-making. 6. A validated questionnaire/scale to assess the impact of access to healthcare services should be developed.…”

Section: Recommendations For Further Researchmentioning

confidence: 99%

See 2 more Smart Citations

A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial

Prescott¹,

Kunkler²,

Williams³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned r...

show abstract

Section: Breast Cancer In Older Patientsmentioning

confidence: 99%

Section: The Need For Clinical Trials In Older Patientsmentioning

confidence: 99%

See 1 more Smart Citation

A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial

Prescott¹,

Kunkler²,

Williams³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…In clinical practice, it is common that elderly women are offered less CT [3,4], because of the fear that they are less able to tolerate toxicity [5]. Nevertheless, some studies have shown that elderly patients tolerate standard chemotherapy regimes, and even more intensive regimes, almost as well as younger patients [6].…”

mentioning

confidence: 97%

The impact of age on HHealth-Related Quality of Life (HRQoL) and symptoms among postmenopausal women with breast cancer receiving adjuvant chemotherapy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6][7][8] Although treatment in older women may be complicated by comorbidities, impaired functional status, physiological differences, and other factors, [9][10][11][12] the under representation of older women in clinical trials [13][14][15][16][17] and in prognostic marker studies 18 makes it difficult to determine which treatments are most appropriate for approximately 50% of women who are diagnosed with breast cancer. Because the population of women aged 65 years is an expanding segment of the United States population, there is a pressing need in clinical oncology practice for information on breast cancer treatment effectiveness, which most likely will need to come from population-based observational studies.…”

mentioning

confidence: 99%

Recurrences and second primary breast cancers in older women with initial early‐stage disease

Geiger

Thwin

Lash

et al. 2007

Cancer

View full text Add to dashboard Cite

Although glutamate receptor 1 (GluR1)‐containing α‐amino‐3‐hydroxyl‐5‐methyl‐4‐isoxazole‐propionate receptors (GluR1‐AMPARs) are implicated in synaptic plasticity, it has yet to be demonstrated whether endogenous GluR1‐AMPARs undergo activity‐dependent trafficking in vivo to synapses to support short‐term memory (STM) formation. The paradigm of pavlovian fear conditioning (FC) can be used to address this question, because a discrete region—the lateral amygdala (LA)—has been shown unambiguously to be necessary for the formation of the associative memory between a neutral stimulus (tone [CS]) and a noxious stimulus (foot shock [US]). Acquisition of STM for FC can occur even in the presence of protein synthesis inhibitors, indicating that redistribution of pre‐existing molecules to synaptic junctions underlies STM. We employed electron microscopic immunocytochemistry to evaluate alterations in the distribution of endogenous AMPAR subunits at LA synapses during the STM phase of FC. Rats were sacrificed 40 minutes following three CS‐US pairings. In the LA of paired animals, relative to naïve animals, the proportion of GluR1‐AMPAR‐labeled synapses increased 99% at spines and 167% in shafts. In the LA of unpaired rats, for which the CS was never associated with the US, GluR1 immunoreactivity decreased 84% at excitatory shaft synapses. GluR2/3 immunoreactivity at excitatory synapses did not change detectably following paired or unpaired conditioning. Thus, the early phase of FC involves rapid redistribution specifically of the GluR1‐AMPARs to the postsynaptic membranes in the LA, together with the rapid translocation of GluR1‐AMPARs from remote sites into the spine head cytoplasm, yielding behavior changes that are specific to stimulus contingencies. J. Comp. Neurol. 518:4723–4739, 2010. © 2010 Wiley‐Liss, Inc.

show abstract

Special issues related to breast cancer adjuvant therapy in older women

Cited by 18 publications

References 56 publications

A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial

A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial

The impact of age on HHealth-Related Quality of Life (HRQoL) and symptoms among postmenopausal women with breast cancer receiving adjuvant chemotherapy

Recurrences and second primary breast cancers in older women with initial early‐stage disease

Contact Info

Product

Resources

About